Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1CNS 1

Conditions

Zollinger-Ellison Syndrome 1Vipoma 1Somatostatinoma 1Paraganglioma 1Neuroendocrine Tumors 1Insulinoma 1Glucagonoma 1Gliosarcoma 1Glioblastoma 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1

Interventions

Trastuzumab 2tipifarnib 1romidepsin 1pazopanib 1cixutumumab 1Streptozocin 1Sorafenib 1Salts 1Oxaliplatin 1Octreotide 1Leucovorin 1Interleukin-12 Subunit p35 1Interleukin-12 1Gefitinib 1Floxuridine 1Everolimus 1Cisplatin 1Capecitabine 1Bortezomib 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Glucagonoma × Salts × Clear all
NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡